Atrial myxoma is the most common primary cardiac tumor. Their ability to embolize frequently determine the debut with focal acute ischemic central neurological symptoms. We report the case of a man of 17 who suffers sudden loss of consciousness due to cerebral embolism and multiple peripheral embolism with fatal outcome. We must consider the cardiac myxoma in the differential diagnosis in pediatric patients presenting with signs and symptoms suggestive of stroke.
Scimitar Syndrome; low frequency complex congenital anomaly, is characterized by a partial anomalous pulmonary venous drainage; in which the right pulmonary veins, flow directly into the hepatic portion of the VCI. It can be associated with cardiac and pulmonary pathology. We describe four patients with diagnosis of Scimitar Syndrome in our hospital; as well as its evolution and applied therapeutic approach.
Cardiac arrest have secondary co-morbidities, especially neurological outcome. Due to this cirumstances is mandatory to optimized postcardiac arrest management. The objective of this research is to analyze patient's characteristics and outcome after out-hospital cardiac arrest in patients that have undergone therapeutic hypothermia.
We conducted a prospective observational study during a two-year period. We included resuscitated patients over eighteen years old who were admitted in to our intensive care unit. These patients had undergone prolonged resuscitation measures and were included in an implemented post-resuscitation protocol which included therapeutic hypothermia.
Thirty-three patients were analyzed. The median time of cardiopulmonary resuscitation was 31.6 minutes. We observed hypoxic/anoxic encephalopathy in 32.3% of cases. This prognosis was associated in those who smoked (p = .04) and with longer time of cardiac arrest (p = .049). Also, the 66.7% of the patients showed a higher incidence of hypoperfusion (p = .049).
In our series hypothermia could be a useful tool in post-resucitation cardiac arrest managment. We also found that the neurological prognosis was associated to non-modifiable risk factors.
Ventricular assist devices are tools that in recent years have taken on special importance in the treatment of advanced heart failure where other treatment options fail. Besides the use of percutaneous ventricular assist device it has facilitated the handling of them and has allowed more hospitals to access use. This is a review article of percutaneous short-term ventricular assist device available and widely used today, is intended to clarify the most important aspects of its indications and management.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：